Elevation Wealth Partners’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.29M Buy
5,109
+122
+2% +$26.2K 0.39% 43
2026
Q1
$1.08M Sell
4,987
-350
-7% -$77.6K 0.39% 42
2025
Q4
$1.22M Sell
5,337
-173
-3% -$39.4K 0.43% 40
2025
Q3
$1.28M Buy
5,510
+104
+2% +$21.2K 0.46% 40
2025
Q2
$1M Hold
5,406
0.4% 45
2025
Q1
$1.13M Sell
5,406
-146
-3% -$28.4K 0.49% 41
2024
Q4
$987K Sell
5,552
-146
-3% -$26.8K 0.42% 41
2024
Q3
$1.13M Hold
5,698
0.48% 40
2024
Q2
$977K Hold
5,698
0.46% 43
2024
Q1
$1.04M Sell
5,698
-790
-12% -$136K 0.52% 37
2023
Q4
$967K Buy
6,488
+5,004
+337% +$730K 0.58% 35
2023
Q3
$221K Hold
1,484
0.19% 52
2023
Q2
$200K Hold
1,484
0.17% 58
2023
Q1
$237K Buy
+1,484
New +$227K 0.22% 55

Other funds holding ABBV

Elevation Wealth Partners's ABBV Position: Q2 2026 in Review

Elevation Wealth Partners increased its AbbVie (ABBV) stake by 2.4% in Q2 2026, buying an estimated $26.2K and bringing the position to 5,109 shares worth $1.29M. The position accounts for 0.39% of the portfolio, ranked #43.

Elevation Wealth Partners first reported a position in ABBV in Q1 2023 and has held it in 14 quarters since. 1,792 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Elevation Wealth Partners held 5,109 shares of AbbVie worth $1.29M as of Q2 2026.
  • Elevation Wealth Partners bought 122 AbbVie shares in Q2 2026, an estimated $26.2K.
  • AbbVie made up 0.39% of Elevation Wealth Partners's portfolio in Q2 2026, its #43 holding.
  • Elevation Wealth Partners first reported a position in AbbVie in Q1 2023 and has held it in 14 quarters since.
  • 1,792 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Elevation Wealth Partners's 13F filing for Q2 2026, filed 8 Jul 2026.